MX366060B - Polipéptidos derivados de tgfbeta y sus usos. - Google Patents

Polipéptidos derivados de tgfbeta y sus usos.

Info

Publication number
MX366060B
MX366060B MX2015005875A MX2015005875A MX366060B MX 366060 B MX366060 B MX 366060B MX 2015005875 A MX2015005875 A MX 2015005875A MX 2015005875 A MX2015005875 A MX 2015005875A MX 366060 B MX366060 B MX 366060B
Authority
MX
Mexico
Prior art keywords
tgfã
diseases
alk5
interact
ability
Prior art date
Application number
MX2015005875A
Other languages
English (en)
Other versions
MX2015005875A (es
Inventor
Monzón Kalet León
Portilla Tania Carmenate
Rodríguez Saumel Pérez
Meriño Amaury Pupo
Osorio Ángel De Jesús Corria
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366060(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of MX2015005875A publication Critical patent/MX2015005875A/es
Publication of MX366060B publication Critical patent/MX366060B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a particularmente con polipéptidos mutados de la molécula TGFß cuya secuencia primaria tiene una alta homología con la secuencia del TGFß humano; estas muteínas pierden la capacidad de interacción con ALK5 pero conservan la interacción con el resto de los receptores que forman parte del complejo receptor (TßRII y TßRIII); tienen la propiedad de antagonizar la señalización del todas las variantes naturales de los ligandos TGFß, dependiente del reclutamiento de ALK5 en el complejo receptor y tienen un efecto inmunomodulador; la presente invención se relaciona con composiciones farmacéuticas que comprenden como principio activo los polipéptidos o proteínas de fusión divulgados y con el uso terapéutico de los polipéptidos, proteínas de fusión y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como el cáncer, enfermedades que cursan con fibrosis y en enfermedades infecciosas crónicas.
MX2015005875A 2012-11-09 2013-10-30 Polipéptidos derivados de tgfbeta y sus usos. MX366060B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß
PCT/CU2013/000007 WO2014071894A1 (es) 2012-11-09 2013-10-30 POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS

Publications (2)

Publication Number Publication Date
MX2015005875A MX2015005875A (es) 2015-09-10
MX366060B true MX366060B (es) 2019-06-26

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005875A MX366060B (es) 2012-11-09 2013-10-30 Polipéptidos derivados de tgfbeta y sus usos.

Country Status (28)

Country Link
US (1) US9701730B2 (es)
EP (1) EP2918284B1 (es)
JP (2) JP6298823B2 (es)
KR (1) KR102093494B1 (es)
CN (1) CN104902916B (es)
AR (1) AR093391A1 (es)
AU (1) AU2013344022B2 (es)
BR (1) BR112015010145B1 (es)
CA (1) CA2887455C (es)
CL (1) CL2015001252A1 (es)
CO (1) CO7400865A2 (es)
CU (1) CU24181B1 (es)
EA (1) EA031990B1 (es)
ES (1) ES2857176T3 (es)
HK (1) HK1213781A1 (es)
IL (1) IL238621B (es)
JO (1) JO3502B1 (es)
MX (1) MX366060B (es)
MY (1) MY173078A (es)
NZ (1) NZ707850A (es)
PE (1) PE20150890A1 (es)
PH (1) PH12015500807A1 (es)
SG (1) SG11201502980VA (es)
TN (1) TN2015000129A1 (es)
TW (1) TWI615404B (es)
UA (1) UA115678C2 (es)
WO (1) WO2014071894A1 (es)
ZA (1) ZA201504462B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041727A1 (en) * 2016-11-18 2018-05-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087998A1 (en) * 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
WO2000017360A1 (en) * 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
WO2006007509A2 (en) * 2004-06-30 2006-01-19 Molecular Logix, Inc. Epidermal growth factor receptor antagonists and methods of use
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
CA2593697A1 (en) * 2005-01-11 2006-07-20 Molecular Logix, Inc. Pan-her antagonists and methods of use
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
BR112012026718A2 (pt) * 2010-04-22 2017-12-19 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio.

Also Published As

Publication number Publication date
NZ707850A (en) 2019-08-30
TW201431875A (zh) 2014-08-16
ES2857176T3 (es) 2021-09-28
CL2015001252A1 (es) 2015-07-17
IL238621B (en) 2019-12-31
CN104902916B (zh) 2018-04-13
JP6298823B2 (ja) 2018-03-20
BR112015010145B1 (pt) 2022-06-07
CN104902916A (zh) 2015-09-09
AU2013344022B2 (en) 2016-12-15
JP6608473B2 (ja) 2019-11-20
EP2918284B1 (en) 2021-02-17
PE20150890A1 (es) 2015-06-10
JP2018111703A (ja) 2018-07-19
WO2014071894A1 (es) 2014-05-15
KR102093494B1 (ko) 2020-03-26
IL238621A0 (en) 2015-06-30
HK1213781A1 (zh) 2016-07-15
CU24181B1 (es) 2016-04-25
MX2015005875A (es) 2015-09-10
UA115678C2 (uk) 2017-12-11
EP2918284A1 (en) 2015-09-16
ZA201504462B (en) 2018-11-28
US20150284441A1 (en) 2015-10-08
CA2887455A1 (en) 2014-05-15
CU20120158A7 (es) 2014-06-27
SG11201502980VA (en) 2015-06-29
CO7400865A2 (es) 2015-09-30
US9701730B2 (en) 2017-07-11
AU2013344022A1 (en) 2015-05-28
EA031990B1 (ru) 2019-03-29
CA2887455C (en) 2022-05-17
JP2015535000A (ja) 2015-12-07
MY173078A (en) 2019-12-25
BR112015010145A2 (es) 2017-08-22
TN2015000129A1 (en) 2016-10-03
KR20150083848A (ko) 2015-07-20
JO3502B1 (ar) 2020-07-05
EA201590914A1 (ru) 2015-09-30
AR093391A1 (es) 2015-06-03
PH12015500807A1 (en) 2015-06-08
TWI615404B (zh) 2018-02-21

Similar Documents

Publication Publication Date Title
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
MX2016016063A (es) Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
MX2016010953A (es) Proteinas de fc multimericas.
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
WO2017194782A3 (en) Therapeutic targeting of non-cellular structures
MX2016010951A (es) Proteinas de fc multimericas.
WO2014176373A3 (en) Interleukin-10 compositions and uses thereof
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX2013013913A (es) Polipeptidos.
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
EA201690159A1 (ru) Способы и композиции для лечения рака
MY166157A (en) Antibodies to bradykinin b1 receptor ligands
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
MX2015011846A (es) Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.
IN2014DN06920A (es)
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
UA114298C2 (uk) Пептид торк та вакцина, що його містить
TN2015000129A1 (en) POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
GB201118201D0 (en) Novel peptides
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
IT201700009222A1 (it) Composizione per la preparazione del paziente per la colonscopia virtuale

Legal Events

Date Code Title Description
FG Grant or registration